| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b4dd7c320939f7adca44cad3715c843 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J71-0068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J43-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00 |
| filingDate |
2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_702885426d6f76f0ac0e3095fc56dd58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd5c6e3fc887bfc0e71d35e070b104a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e99343c83b2c6805c7501b58828533be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7396a9cb6a33bf5d16bf96caaa850da7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2be59f6876a39616d0b4795356c318b |
| publicationDate |
2022-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022041647-A1 |
| titleOfInvention |
Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
| abstract |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. |
| priorityDate |
2018-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |